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ABSTRACT
Background. Direct-acting antiviral agents (DAAs) have shown high rates of sustained virological response in chronic
hepatitis C virus (HCV) infection. However, the influence of DAAs on the course of kidney involvement in HCV-associated
mixed cryoglobulinaemia (HCV-MC) has been little studied. The aim of this study was to analyse the effects of antiviral
treatment on kidney prognosis and evolution in patients diagnosed with HCV-MC.
Methods. The RENALCRYOGLOBULINEMIC study is an observational multicentre cohort study of 139 patients with HCV-MC
from 14 Spanish centres. Clinical and laboratory parameters were measured before and after antiviral treatment. Primary
endpoints were kidney survival and mortality after HCV-MC diagnosis. Secondary endpoints were clinical, immunological
and virological responses after antiviral treatment.
Results. Patients were divided into three groups based on the treatment received: treatment with DAAs (n¼100) treatment
with interferon (IFN) and ribavirin (RBV) (n¼24) and no treatment (n¼15). Patients were followed up for a median duration
of 138 months (interquartile range 70–251. DAA treatment reduced overall mortality {hazard ratio [HR] 0.12 [95% confidence
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interval (CI) 0.04–0.40]; P<0.001} and improved kidney survival [HR 0.10 ( 95% CI 0.04–0.33); P<0.001].
Conclusions. Results from the RENALCRYOGLOBULINEMIC study indicated that DAA treatment in patients with HCV-MC
improves kidney survival and reduces mortality.
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INTRODUCTION
Hepatitis C virus (HCV) infection is associated with numerous
extrahepatic manifestations, including kidney disease.
Cryoglobulins are detected in up to 50% of patients with chronic
HCV at some point during their infection, but only 2–3% will de-
velop vasculitis symptoms, defined as HCV-related mixed cryo-
globulinaemia (HCV-MC). HCV-MC reflects the activation of B
cells, generating pathogenic immunoglobulins: monoclonal im-
munoglobulin M (IgM) with rheumatoid factor (RF) activity and
polyclonal IgG (type II) or polyclonal IgG and polyclonal IgM
(type III) [1, 2]. The most frequent presentations include palpa-
ble purpura, arthralgia, weakness, myalgia, polyneuropathy, in-
testinal ischaemia and cryoglobulinaemic glomerulonephritis.
More than half of patients have hypocomplementaemia [3].
Typical kidney manifestations of HCV-MC include hyperten-
sion, proteinuria, microscopic haematuria, kidney failure and
nephrotic syndrome [4]. The gold standard for diagnosis of
HCV-MC is kidney biopsy. Light microscopy shows membrano-
proliferative glomerulonephritis in most cases (60–80%), due to
deposition of mesangial and subendothelial immune com-
plexes, with thickening of the glomerular basement membrane
and a ‘double-contoured’ appearance [5]. Immunofluorescence
examination reveals characteristic mesangial and capillary wall
deposition of IgM, IgG and complement component 3 (C3).
Subendothelial deposits can be observed on electron micros-
copy. Kidney involvement in patients with HCV-MC has been
frequently associated with unfavourable clinical and virological
response [6].
Treatment for HCV infection has changed in the past few
years with the introduction of direct-acting antiviral agents
(DAAs) that have improved sustained virological response (SVR)
compared with pegylated interferon–ribavirin (IFN 6 RBV) [7–
14]. DAAs have yielded high rates of SVR in chronic HCV infec-
tion, even in patients with chronic kidney disease (CKD) [15].
However, only limited data on kidney outcomes in HCV-MC
patients are available due to the small number of patients in-
cluded in previous studies.
The aim of this study was to evaluate kidney survival and
mortality in patients with HCV-MC treated with DAAs com-




The RENALCRYOGLOBULINEMIC study is a Spanish observa-
tional retrospective multicentre cohort study including 139
patients with HCV-MC from 14 nephrology departments that
are part of the Spanish Glomerular Study Group (GLOSEN).
Study population
Inclusion criteria were age >18 years and diagnosis of HCV-MC
with or without kidney biopsy. Patients could be treated with
DAAs or IFN 6 RBV or untreated for HCV. Kidney involvement
was defined by the presence of cryoglobulinaemic glomerulone-
phritis with a membranoproliferative pattern of injury on histo-
logical examination of kidney biopsy or by the presence of
proteinuria or haematuria or an estimated glomerular filtration
rate (eGFR) <60 mL/min/1.73 m2 without an alternative cause for
CKD in patients without kidney biopsy. Proteinuria was quanti-
fied by the urinary protein:creatinine ratio using either spot
urine samples or 24-h urine samples when available. The pres-
ence of urinary haem was determined by dipstick analysis. HCV
cryoglobulinaemia was assessed by serology in terms of cryocrit
percentage, serum complement levels (C3 and C4) and RF.
Exclusion criteria were renal replacement therapy (dialysis
or kidney transplant) and human immunodeficiency virus
infection.
Baseline clinical evaluation included age, gender, hyperten-
sion, diabetes, dyslipidaemia, obesity, glomerulonephritis, pur-
pura, arthralgia, skin ulcer, peripheral neuropathy, serum
creatinine, eGFR, proteinuria, albuminuria, haematuria, kidney
biopsy, cryoglobulinaemia type II or III, cirrhosis, HCV genotype,
previous HCV treatment, duration of HCV treatment, virological
response, hepatic transplant, HCV RNA level log10, alanine ami-
notransferase, plasma albumin, cryocrit percentage, C3 and C4
levels, positive RF and treatment received (renin–angiotensin
system blockers, plasmapheresis, corticosteroids, rituximab, cy-
clophosphamide, furosemide).
Study endpoints
For all patients, the date of diagnosis of HCV infection was
established as the baseline time point. Follow-up duration was
defined as the interval between HCV diagnosis and the last out-
patient visit, death or loss to follow-up. Kidney event was de-
fined as duplication on baseline creatinine level or dependence
on renal replacement therapy. Primary endpoints of the study
were kidney survival and mortality. Secondary endpoints of the
study were clinical, virological and immunological responses
following antiviral treatment.
Treatment and outcomes
Patients were divided into three groups based on HCV treatment
given: DAAs, IFN 6 RBV and no treatment. Different treatment
combinations with the newly licensed DAAs in Spain were
used, according to the European Association for the Study of the
Liver guidelines [16]. The type of HCV treatment given was de-
pendent on the clinician’s choice and documented when avail-
able. SVR was defined as undetectable HCV RNA levels 12 weeks
after treatment cessation. Serum HCV RNA was quantified by
polymerase chain reaction assay.
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Serum creatinine, eGFR and proteinuria measured at HCV di-
agnosis (baseline), at the end of HCV treatment and at the end
of follow-up were recorded. Data on cryocrit percentage and C3
and C4 levels were also collected at baseline, at the end of treat-
ment and at the end of follow-up. Data on duplication on creati-
nine levels, dependence on renal replacement therapy and
mortality were retrieved.
Statistics
Results were expressed as mean 6 standard deviation (SD) for
continuous variables. If data were not normally distributed, me-
dian values with the interquartile range (IQR) were reported. For
categorical variables, the number of patients affected/total (per-
centage) was used. Comparisons of variables at baseline, at the
end of treatment and at the end of follow-up were made using a
paired sample test.
Kaplan–Meier and Cox proportional hazards analyses were
performed to evaluate the effects of DAAs on kidney survival
and mortality. To identify the possible factors involved in kid-
ney survival, univariate and multivariate Cox regression models
were used. The covariates included in the model were selected
based on clinical criteria and results of the univariate analysis.
The covariates included in the Cox regression model for kidney
survival were eGFR and proteinuria at HCV diagnosis and the
type of HCV treatment given. The covariates included in the Cox
regression model for mortality were age, eGFR and proteinuria
at HCV diagnosis and the type of HCV treatment given. To avoid
biases due to potentially more comorbidities in the group of
untreated patients, analyses using Cox regression models were
separately conducted using the type of antiviral treatment and
different comorbidity variables, including hypertension, diabe-
tes, dyslipidaemia and obesity. Statistical significance was de-
fined as P< 0.05.
RESULTS
Patients characteristics
In total, 139 patients with HCV-MC were included. Overall, 100
patients received DAAs and 24 were treated with IFN 6 RBV,
while 15 did not receive antiviral treatment.
Demographic, clinical and other baseline characteristics of
patients according to treatment are shown in Table 1. At base-
line, mean serum creatinine level was 1.4 mg/dL, mean eGFR
was 56 mL/min and mean proteinuria was 2.1 g/day.
Haematuria was detected in 68% of patients. In 65 patients
(46.8%), histopathological examination of kidney biopsy
revealed glomerulonephritis with a membranoproliferative pat-
tern. Seventy-five per cent of patients had genotype 1b. No sta-
tistically significant differences were found between the
different patient groups in relation to comorbidities (hyperten-
sion, diabetes, dyslipidaemia and obesity).
Primary endpoints: kidney survival and mortality
To avoid biases due to potentially more comorbidities in
untreated patients and those treated with IFN 6 RBV compared
with patients treated with DAAs, different models of kidney sur-
vival were applied and adjusted for each of the comorbidity var-
iables. The type of HCV treatment was found to maintain
consistently its independent predictive power of kidney survival
(Table 2). Over a median follow-up duration of 138 months (IQR
70-251), there were three (20%) kidney events in untreated
patients, six (25%) in patients treated with IFN 6 RBV and six
(6%) in those treated with DAAs. Kidney survival was signifi-
cantly higher in patients treated with DAAs (log rank 19.718;
P< 0.001) (Figure 1). Using the Cox regression model adjusted
for baseline eGFR and proteinuria, we found patients treated
with DAAs had a lower risk for duplication on baseline creati-
nine values or for dependence on renal replacement therapy
{hazard ratio [HR] 0.10 [95% confidence interval (CI) 0.04–0.33];
P< 0.001}. Therefore treatment with DAAs reduced the risk for a
kidney event by 90%.
There were 10 (66.6%) deaths among untreated patients, 9
(37.5%) among those treated with IFN 6 RBV and 4 (4%) among
those treated with DAAs. Mortality in patients treated with
DAAs was significantly lower compared with historical controls
treated with IFN 6 RBV, and lower than in untreated patients
(log rank 54.507; P< 0.001) (Figure 2). Using the Cox regression
model adjusted for age, baseline eGFR and proteinuria, patients
treated with DAAs had lower mortality [HR 0.12 (95% CI 0.04–
0.40); P< 0.001]. Therefore treatment with DAAs reduced mor-
tality by 88%.
Secondary endpoints: clinical, virological and
immunological responses
When we studied the effects of antiviral treatment on kidney
disease, we observed a significant decrease in daily proteinuria
in patients treated with DAAs at the end of treatment (1.3 g/day
versus 2.4 g/day at baseline; P¼ 0.003) and at the end of follow-
up (0.9 g/day versus 2.4 g/day at baseline; P< 0.001) (Figure 3). In
patients treated with IFN 6 RBV, a trend towards a decrease in
proteinuria was observed following antiviral treatment, al-
though the difference was not statistically significant.
No significant change in eGFR was observed, regardless of
DAA treatment (Figure 4).
In patients treated with DAAs, cryocrit percentages at the
end of treatment (1.7 6 2%) and at the end of follow-up
(0.7 6 1.8%) were significantly decreased (P¼ 0.001) compared
with pre-treatment levels (5 6 4.4%). Moreover, in patients
treated with DAAs, C3 and C4 levels increased significantly at
treatment cessation compared with pre-treatment levels (C3
levels 32 6 41 versus 101 6 30 mg/dL, respectively, P< 0.001; C4
levels 5 6 6 versus 14 6 18 mg/dL, respectively, P< 0.001) and at
the end of follow-up compared with pre-treatment levels (C3
levels 32 6 41 versus 100 6 24 mg/dL, P< 0.001; C4 levels 5 6 6
versus 20 6 24 mg/dL, P< 0.001). No significant changes in cryo-
crit percentage and C3 and C4 levels were observed in patients
treated with IFN 6 RBV.
In terms of virological response, patients with SVR had sig-
nificantly lower mortality than those without SVR (log rank
18.611; P< 0.001).
In total, 98% of patients treated with DAAs achieved SVR
12 weeks after treatment cessation compared with 43.5% of
patients treated with IFN 6 RBV regimens. When we analysed
all patients who achieved SVR and compared those treated with
DAAs with those treated with IFN 6 RBV, mortality was signifi-
cantly lower in patients treated with DAAs (log rank 7.939;
P¼ 0.005).
DISCUSSION
To our knowledge, the RENALCRYOGLOBULINEMIC study is the
first multicentre study including a large number of HCV-MC
patients treated with DAAs that evaluates kidney survival and
long-term mortality. The paradigm of HCV infection has
changed radically in recent years with the introduction of
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DAAs. Growing evidence supports the efficacy and safety of
DAAs in the treatment of HCV infection. Several studies have
shown similar high rates of SVR and clinical remission in the
setting of cryoglobulinaemic vasculitis with HCV infection after
treatment with DAAs [12–15]. In addition, patients treated with
DAAs achieve higher SVR, compared with those treated with
IFN 6 RBV regimens. DAAs have a good safety profile and are
well tolerated in patients with HCV and CKD [17]. However, lim-
ited data are available regarding long-term effects of DAAs on
kidney function in patients with HCV-MC. To date, the number
of patients diagnosed with both HCV-CM and CKD included in
studies have been too small to draw conclusions. In addition,
the follow-up duration of these patients is, in general, too short
to analyse kidney survival and long-term mortality.
In a study of seven patients with kidney involvement, Sise et
al. [18] showed a modest improvement in median eGFR (52.7 to
59.7 mL/min/1.73 m2) after DAA treatment. The authors also
found a reduction in median proteinuria after treatment with
Table 1. Baseline characteristics of patients according to HCV treatment
Characteristics
Global Untreated IFN 6 RBV DAA
(n¼ 139) (n¼ 15) (n¼ 24) (n¼ 100)
Age (years) 65 6 12 70 6 15 65 6 14 65 6 10
Male gender (%) 51 66.7 58.3 46
Hypertensive (%) 53 60 58.3 51
Diabetes (%) 17 26.7 12.5 17
Dyslipidaemia (%) 12 20 12.5 11
Obesity (%) 10 20 4.2 10
Baseline clinical presentation
Glomerulonephritis, % (n) 46.8 (65) 53.3 (8) 83.3 (20) 37 (37)
Purpura (%) 46 13 50 60
Arthralgia (%) 32 26 21 42
Skin ulcer (%) 6 6 5.3 8.4
Peripheral neuropathy (%) 25 6.7 12.5 36
CKD
Serum creatinine (mg/dL) 1.4 6 1.1 1.9 6 0.7 1.6 6 0.7 1.4 6 1.1
eGFR (mL/min) 56 6 26 35 6 22 47 6 20 51 6 26
Proteinuria (g/day) 2.1 6 3 3.7 6 4.4 2.9 6 3.8 1.6 6 2.3
Microhaematuria (%)
No 32 14 5 11
1–5 red blood cells per field 30 40 25 36
5–10 red blood cells per field 10 13 14 14
>20 red blood cells per field 28 33 56 39
Plasma albumin (g/dL) 3.8 6 0.6 2.9 6 0.8 3.6 6 1.06 3.8 6 0.6
Kidney biopsy, % (n) 46.8 (65) 53.3 (8) 83.3 (20) 37 (37)
Cryoglobulinaemia (%)
Type II 74 70 50 80
Type III 26 40 50 20
Cirrhosis (%) 44 40 25 50
Genotype 1b (%) 75 60 70.8 78
Previously treated (%) 27 7 17 37
Duration of treatment (months) 20 6 12 36 6 17 16 6 6
Virological response (%)
Non-sustained response 20 56.5 2
Sustained response 80 43.5 98
Hepatic transplant, % (n) 5.8 (8) 17 (2) 5 (1) 5 (5)
Baseline laboratory findings
HCV RNA level log10 (IU/mL) 5.7 6 1 5.8 6 0.6 5.2 6 1.4 5.8 6 1.1
Alanine aminotransferase (IU/mL) 63 6 54 66 6 66 62 6 54 63 6 53
Cryocrit (%) 6 6 7 6.8 6 13 8.5 6 9 5 6 4.3
Baseline C3 (mg/dL) 71 6 43 74 6 30 78 6 36 62 6 43
Baseline C4 (mg/dL) 8 6 8.5 15 6 6.4 7.7 6 8.1 7 6 8
Positive RF 254 6 551 290 6 140 293 6 320 267 6 616
Treatment (%)
Renin–angiotensin system blockers 65 73 79 61
Plasmapheresis 16 13 42 10
Corticosteroids 45 27 54 45
Rituximab 25 13 29 26
Cyclophosphamide 4 0 12 3
Furosemide 39 40 46 37
Values are presented as mean 6 SD unless states otherwise.
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DAAs (from 3514 to 1244 mg/g albumin:creatinine ratio, al-
though it was measured quantitatively in only three patients).
Similar findings were seen in other studies. In four patients
with kidney failure, Gragnani et al. [19] showed all four experi-
enced a marked improvement in eGFR with normalization of
proteinuria. Bonaccy et al. [14] showed a complete clinical re-
sponse in five of seven (71%) patients with vasculitis nephropa-
thy and found an improvement in median eGFR from 40 to
54 mL/min/1.73 m2 and a decrease in median proteinuria from
1.4 to 0.17 g/dL. Saadoun et al. [12] evaluated the response to
DAA treatment in a prospective multicentre study that included
five patients with kidney injury. Proteinuria decreased from 0.9
to 0.2 g in a 24-h urine test and haematuria disappeared in 80%
of cases at week 24. Another published series by Emery et al. [13]
including 10 patients with HCV-MC and kidney manifestations
showed complete remission in 30% of patients, with recovery in
median eGFR from 48.5 to 58.1 mL/min/1.73 m2. Proteinuria was
reduced from a median of 0.3 to 0.1 g/dL after treatment with
DAAs. In our study, we did not find changes in eGFR in patients
with HCV-MC after treatment with DAAs. However, we found a
statistically significant decrease in proteinuria in patients
treated with DAAs, which was not significant in patients treated
with IFN 6 RBV. The novelty of our findings is the tremendously
beneficial effect of DAAs on long-term kidney survival and over-
all mortality, regardless of the initial GFR, proteinuria and age.
Recently Sise et al. [20] published a large retrospective obser-
vational study in which they evaluated the kidney response in
1178 patients with CKD and HCV infection after treatment with
DAAs. The authors showed stabilization in eGFR decline
(1.32 mL/min/year, previous decline of 5.998 mL/min/year)
and a significant improvement in albuminuria (except in dia-
betic CKD patients, who experienced a decline in eGFR and
worsening of albuminuria). They concluded that DAAs slowed
the rate of eGFR decline in patients with impaired kidney func-
tion at baseline. Although this study had a large number of
patients, it included all causes of CKD, not HCV-MC only, and
while it analysed surrogate kidney endpoints, strong
endpoints such as renal replacement therapy or mortality were
not included in their analysis.
Our study brings further supporting evidence to the current
recommendations of the Kidney Disease: Improving Global
Outcomes 2018 guidelines on the use of DAAs [21], which is now
recommended as the first-line therapy in cryoglobulinaemic
FIGURE 1: Kaplan–Meier curve showing kidney survival in patients treated with
DAAs (group 1), those treated with IFN 6 RBV (group 2) and untreated patients
(group 3).
Table 2. Effects of comorbidities and types of antiviral treatment on kidney survival (Cox regression model)
Model 1 Model 2 Model 3 Model 4








Hypertension HR 2.065 (0.701–6.079)
Dyslipidaemia HR 2.621 (0.803–8.554)
Obesity HR 0.822 (0.382–1.766)
Diabetes HR¼ 1.746 (0.483–6.320)
FIGURE 2: Kaplan–Meier curve showing mortality in patients treated with DAAs
(group 1), those treated with IFN 6 RBV (group 2) and untreated patients
(group 3).
FIGURE 3: Proteinuria at baseline, at the end of treatment and at the end of fol-
low-up in patients treated with DAAs (group 1), those treated with IFN 6 RBV
(group 2) and untreated patients (group 3).
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glomerulonephritis’. Immunosuppression is reserved for
patients with severe manifestations or those who do not enter
remission after achieving SVR with DAA treatment.
In terms of SVR, in the RENALCRYOGLOBULINEMIC study,
98% of patients treated with DAAs achieved SVR compared with
43.5% of patients treated with IFN 6 RBV regimens. Other stud-
ies [6] have previously shown that patients treated with DAAs
have higher rates of SVR compared with those who received
IFN 6 RBV. We found a significant relationship between SVR
and mortality. Patients who achieved SVR had lower mortality
(log rank 18.611; P< 0.001). This finding is consistent with other
studies in which clinical remission in patients with HCV-MC is
associated with SVR status [11, 13–16]. However, in our study we
found that among patients who achieved SVR, those treated
with DAAs had lower mortality than patients treated with
IFN 6 RBV. In the previous studies mentioned above, the SVR
rate in patients with cryoglobulinaemia treated with DAAs was
between 86% and 100%. Bonaccy et al. [14] reported that all
patients with cryoglobulinaemia and kidney involvement (n ¼
7) achieved SVR after treatment with DAAs. The authors also
showed that SVR was associated with clinical and immunologi-
cal improvement in most patients. Taken together, these find-
ings are in agreement with our study results.
Regardless of the immunological response, we analysed data
on complement (C3 and C4) levels and cryocrit percentages be-
fore and after treatment. Hypocomplementaemia and increased
cryocrit percentage have been considered traditionally as
markers of active cryoglobulinaemic glomerulonephritis [3–5],
but there is a paucity of data on the response of these two
markers after treatment with DAAs. Sise et al. [17] observed cry-
ocrit negativization in three of seven patients after treatment
with DAAs, with a decrease in cryocrit percentage in the
remaining four patients from 3% to 1.5%. Bonaccy et al. [14] also
detected an increase in complement levels (median C4 from
0.02 to 0.12 g/L) and a reduction in cryocrit percentage (3.2% to
0.5%) after treatment with DAAs. Finally, in Emery et al.’s [13]
study there was a remarkable reduction in median cryocrit per-
centage (4.5% to 0.5%) at the time of SVR. In our study, we also
found a statistically significant increase in serum complement
levels and a decrease in cryocrit percentage after treatment
with DAAs. However, 6 of the 139 patients (4.3%) did not achieve
immunological remission; this is because HCV infection causes
sustained immunological alteration of B lymphocytes that is
sometimes perpetuated over time, regardless of the eradication
of RNA-HCV.
Our study has some important limitations. First, the number
of patients with HCV-MC who were untreated (n¼ 15) and those
who were treated with IFN 6 RBV (n¼ 24) was too small com-
pared with the size of the DAA treatment group. Although
untreated patients had higher proteinuria and worse renal func-
tion at baseline, these variables were adjusted using the Cox re-
gression model. Second, this is a retrospective multicentre
study with a long follow-up period. This implies that there is a
high level of heterogeneity of patients receiving HCV treatment
in terms of the types and doses of antiviral treatment, as well as
of variables that were not included in the analysis. Despite
these limitations, the main strength of our study is the large
number of patients with HCV-MC included and the long follow-
up duration, allowing the assessment of kidney survival and
mortality following DAA treatment.
In conclusion, the RENALCRYOGLOBULINEMIC study sug-
gests that DAA treatment in patients with HCV-MC improves
kidney survival and reduces mortality.
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